| Followers | 59 |
| Posts | 7595 |
| Boards Moderated | 0 |
| Alias Born | 10/20/2014 |
Thursday, June 25, 2020 7:45:04 AM
AMRN will lay a great Cardiovascular medication to waste if it
continues with the misguided strategy of GIA! Vascepa should be one
of the most used medications of all time, but only if it is placed
in the hands of BP! Adam Feuerstein warned that AMRN was playing
on Cardiovascular turf...and that JT could become a "Wall Street Hero"
if he were to sell AMRN to BP. Did JT ever receive any credible BO
offers? (Rumours were that offers were made and that JT may have
decided they were inadequate.) Perhaps JT truly believed AMRN was
worth far more than any BP was willing to pay. Vascepa is still a
great drug...and may be very valuable if it is in the right hands.
If Vascepa is left in the wrong hands, it runs the risk of being
"laid to waste." If JNJ owned Vascepa there would be speculation
of Vascepa's potential to ameleorate residual inflammation as a
result of COVID-19. How ironic that not only may the full potential
of Vascepa to treat CVD might be missed...but also its potential
to help heal from the ravages of COVID-19 as well.
continues with the misguided strategy of GIA! Vascepa should be one
of the most used medications of all time, but only if it is placed
in the hands of BP! Adam Feuerstein warned that AMRN was playing
on Cardiovascular turf...and that JT could become a "Wall Street Hero"
if he were to sell AMRN to BP. Did JT ever receive any credible BO
offers? (Rumours were that offers were made and that JT may have
decided they were inadequate.) Perhaps JT truly believed AMRN was
worth far more than any BP was willing to pay. Vascepa is still a
great drug...and may be very valuable if it is in the right hands.
If Vascepa is left in the wrong hands, it runs the risk of being
"laid to waste." If JNJ owned Vascepa there would be speculation
of Vascepa's potential to ameleorate residual inflammation as a
result of COVID-19. How ironic that not only may the full potential
of Vascepa to treat CVD might be missed...but also its potential
to help heal from the ravages of COVID-19 as well.
Recent AMRN News
- Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) • IH Market News • 05/27/2026 03:24:38 PM
- New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
